Blackstone Life Sciences invests $250M in Anagram Therapeutics to advance ANG003, a novel oral enzyme therapy for pancreatic insufficiency. Learn more.
Popular Searches:
Recommended Posts
Search Results
Blackstone Life Sciences invests $250M in Anagram Therapeutics to advance ANG003, a novel oral enzyme therapy for pancreatic insufficiency. Learn more.
Stryker acquires Amplitude Vascular Systems, adding next-gen intravascular lithotripsy tech to strengthen peripheral arterial disease treatment.
